Utility of FDG-PET in immunotherapy: results from a Phase II study of NSCLC patients undergoing therapy with the PD-L1 inhibitor, atezolizumab (MPDL3280A)
Year: 2016
Type: article
Authors: Jill Fredrickson, Jason Callahan, Roel Funke, Sandra Sanabria, Wolfgang E. J. Weber, Alex de Crespigny, Rodney J. Hicks
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2434151164